Predisposition to the appearance of thrombotic complications in diabetic patients is associated with mutational defects in the coagulation system, particularly in the methylenetetrahydrofolate reductase gene (S677T) in the gene for factor V clotting (G1691A) and the gene factor II (G20210A) of blood coagulation. These mutations are associated with an increase in blood coagulation potential, as well as hyperactivation of platelets.
